Caswell, Deborah R;
Gui, Philippe;
Mayekar, Manasi K;
Law, Emily K;
Pich, Oriol;
Bailey, Chris;
Boumelha, Jesse;
... Swanton, Charles; + view all
(2023)
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nature Genetics
10.1038/s41588-023-01592-8.
(In press).
Preview |
Text
s41588-023-01592-8.pdf - Published Version Download (12MB) | Preview |
Abstract
In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC) enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung cancer was assessed. A3B expression in EGFR mutant (EGFRmut) non-small-cell lung cancer (NSCLC) mouse models constrained tumorigenesis, while A3B expression in tumors treated with EGFR-targeted cancer therapy was associated with treatment resistance. Analyses of human NSCLC models treated with EGFR-targeted therapy showed upregulation of A3B and revealed therapy-induced activation of nuclear factor kappa B (NF-κB) as an inducer of A3B expression. Significantly reduced viability was observed with A3B deficiency, and A3B was required for the enrichment of APOBEC mutation signatures, in targeted therapy-treated human NSCLC preclinical models. Upregulation of A3B was confirmed in patients with NSCLC treated with EGFR-targeted therapy. This study uncovers the multifaceted roles of A3B in NSCLC and identifies A3B as a potential target for more durable responses to targeted cancer therapy.
Archive Staff Only
 |
View Item |
